Central serous chorioretinopathy in active endogenous Cushing’s syndrome

被引:0
|
作者
Joost Brinks
Femke M. van Haalen
Thomas J. van Rijssen
Nienke R. Biermasz
Onno C. Meijer
Alberto M. Pereira
Camiel J. F. Boon
Elon H. C. van Dijk
机构
[1] Leiden University Medical Center,Department of Ophthalmology
[2] Leiden University Medical Center,Department of Medicine, Division of Endocrinology, and Center for Endocrine Tumors
[3] Academic Medical Centers,Department of Ophthalmology
[4] University of Amsterdam,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Multiple case series have provided evidence for a relatively high incidence of central serous chorioretinopathy (CSC) in patients with active Cushing’s syndrome (CS). We describe the ophthalmological status in detail of consecutive patients with active endogenous CS (either de novo or recurrent active endogenous CS) in this prospective cohort study. All patients underwent complete ophthalmological examination, including multimodal imaging, which was performed shortly after establishing the diagnosis of active CS in hypercortisolemic state. Eleven CS patients (4 men, 7 women) with active hypercortisolism were included. Abnormalities reminiscent of (subclinical) CSC were found in 3 patients. Optical coherence tomography (OCT) revealed macular subretinal fluid in 1 patient, who was diagnosed as having active CSC and was successfully treated with half-dose photodynamic therapy. Two other patients showed CSC-like abnormalities: an unilateral pseudovitelliform lesion on OCT and hyperfluorescent changes on fluorescein angiography in one patient, and unilateral leakage on fluorescein angiography in the other patient. Mean subfoveal choroidal thickness on enhanced depth imaging OCT was 270 ± 40 μm (range, 178 – 357 μm). Retinal abnormalities resembling (subclinical) CSC may be more common than previously thought in patients with active CS, and may exist even in patients without visual complaints. Clinicians should have a low threshold for ophthalmological evaluation in case of a CS patient with visual symptoms since there may be therapeutic opportunities to prevent vision loss.
引用
收藏
相关论文
共 50 条
  • [41] Central serous chorioretinopathy and antiphospholipid syndrome: Three cases report
    Billoir, Paul
    Michon, Adrien
    Darnige, Luc
    LUPUS, 2021, 30 (03) : 514 - 517
  • [42] Traumatic central serous chorioretinopathy
    Steeples, Laura
    Sharma, Vinod
    Mercieca, Karl
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2015, 63 (06) : 536 - 538
  • [43] Photopigments in Central Serous Chorioretinopathy
    Ojima, Akira
    Iida, Tomohiro
    Sekiryu, Tetsuju
    Maruko, Ichiro
    Sugano, Yukinori
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2011, 151 (06) : 940 - 952
  • [44] Central Serous Chorioretinopathy Classification
    Vilela, Manuel
    Mengue, Carolina
    PHARMACEUTICALS, 2021, 14 (01) : 1 - 9
  • [46] FAMILIAL CENTRAL SEROUS CHORIORETINOPATHY
    van Dijk, Elon H. C.
    Schellevis, Rosa L.
    Breukink, Myrte B.
    Mohabati, Danial
    Dijkman, Greet
    Keunen, Jan E. E.
    Yzer, Suzanne
    Den Hollander, Anneke I.
    Hoyng, Carel B.
    de Jong, Eiko K.
    Boon, Camiel J. F.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (02): : 398 - 407
  • [47] CENTRAL SEROUS CHORIORETINOPATHY AND PREGNANCY
    SUNNESS, JS
    HALLER, JA
    FINE, SL
    ARCHIVES OF OPHTHALMOLOGY, 1993, 111 (03) : 360 - 364
  • [48] Brachytherapy for Central Serous Chorioretinopathy
    Supriya Arora
    Baldassarre D. Stea
    Russell J. Hamilton
    Jay Chhablani
    Ophthalmology and Therapy, 2022, 11 : 1611 - 1616
  • [49] Central serous chorioretinopathy and glucocorticoids - Author's response
    Bouzas, EA
    Karadimas, P
    SURVEY OF OPHTHALMOLOGY, 2004, 49 (01) : 129 - 129
  • [50] Central serous chorioretinopathy: A review
    Fung, Adrian T. T.
    Yang, Yi
    Kam, Andrew W. W.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 51 (03): : 243 - 270